Supplemental Digital Content 1 Hemagglutination-inhibition (HI) antibodies against A/New Caledonia/20/99 [H1N1], A/Wisconsin/67/2005 [H3N2] and B/Malaysia/2506/2004.

Slides:

Advertisements

Similar presentations

Two dose Q-HPV Vaccine Study

Advertisements

Vaccines What is new ? Umayya M.Musharrafieh, MD American University of Beirut Medical Center November 10-12, 2006.

Children Aged 5 to

HPV Vaccines: What We Know and What We Should Expect Laura Koutsky, PhD Professor of Epidemiology University of Washington Seattle, WA.

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.

Vaccines and Related Biological Products

1 Alberta’s Influenza Immunization Program TARRANT Workshop Elaine Sartison AHW March

Avian and Pandemic Influenza Vaccine Development John Treanor Professor of Medicine University of Rochester Medical Center Rochester, NY.

Hepatitis A and Hepatitis A Vaccine Epidemiology and Prevention of Vaccine- Preventable Diseases National Immunization Program Centers for Disease Control.

Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products OVRR/CBER/FDA Prepared for Vaccines and Related Biological Products Advisory.

HPV Vaccine Update Eileen Yamada, MD, MPH Immunization Branch California Department of Health Services.

Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products OVRR/CBER/FDA Prepared for Vaccines and Related Biological Products Advisory.

National Vaccine Advisory Committee November 29, 2005 Update on NIH H5N1 Vaccine Trials Linda C. Lambert Chief, Respiratory Diseases Branch Division of.

Vaccines and Related Biological Products Advisory Committee Presentation on Sanofi Pasteur’s H5N1 Vaccine Andrea N. James, M.D. Senior Medical Officer.

Life Years Lost (2010, most recent available) Trauma injury accounts for 30% of all life years lost in the U.S. Cancer accounts for 16% Heart disease.

Viral Hepatitis - Historical Perspective A “Infectious” “Serum” Viral hepatitis Entericallytransmitted Parenterallytransmitted F, G, ? other E NANB BD.

“FluBlØk: A Recombinant Hemagglutinin Protein Vaccine for Influenza” Manon Cox VRBPAC February 27, 2007 A Vaccine Company for the 21st Century “Making.

Meningococcal A,C,Y,W135 Conjugate Vaccine (Menactra TM ) Lucia H. Lee CBER, FDA Vaccines and Related Biological Products Advisory Committee Meeting September.

Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products Prepared for Vaccines and Related Biological Products Advisory Committee.

Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products OVRR/CBER/FDA Prepared for Vaccines and Related Biological Products Advisory.

1 Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed (Tdap, ADACEL™) Aventis Pasteur, Ltd. VRBPAC – March 15, 2005 ChrisAnna.

GEOMETRIC MEAN Take the log value of each sample (log button on the calculator) Add the log value of each sample together Divide by the number of samples.

Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (Q-Pan H5N1 Vaccine) Manufactured by GlaxoSmithKline Vaccines and Related Biological Products Advisory.

FDA/CBER Vaccines and Related biological Products Advisory Committee Meeting Discussion of Clinical Trials to Support use of Vaccines against the 2009.

INFLUENZA UPDATE DEBBYE ROSEN ADULT IMMUNIZATION COORDINATOR CONNECTICUT DEPARTMENT OF PUBLIC HEALTH

VACCINES AND RELATED BIOLOGICAL PRODUCTS ADVISORY COMMITTEE CBER Regulatory Approaches & Activities To Support Licensure of Pandemic (H1N1) 2009 Vaccine.

Hepatitis A Issues and IAPCOI perspectives Dr Monjori Mitra Associate Professor Institute of Child Health Kolkata.

Influenza A (H1N1) Vaccine Vaccines and Related Biological Products Advisory Committee Meeting, 23 July 2009 Raburn Mallory, M.D. Proprietary Vaccines.

2015 Connecticut Influenza Update Mick Bolduc Connecticut Immunization Program December 15,

Developing a Vaccine to Protect Against Pandemic Influenza Public Statement by GlaxoSmithKline 27 February 2007.

M M M M 5. Not Listed

Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products Prepared for Vaccines and Related Biological Products Advisory Committee.

DoD Global Influenza Surveillance Program Sentinel Site Surveillance at AFIOH Sequence Analysis And Vaccine Effectiveness Overview Luke T. Daum, PhD, Molecular.

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.

1 13-valent pneumococcal conjugate vaccine (PCV13) – new ACIP recommendations 44 th National Immunization Conference April 21, 2010 Pekka Nuorti, MD, DSc.

网上报账系统包括以下业务：日常报销差旅费报销借款业务 1. 填写报销内容 2. 选择支付方式（或冲销借款） 3. 提交预约单 4. 打印预约单并同分类粘贴好的发票一起送至财务处预约报销步骤：网上报账系统薪酬发放管理系统财务查询系统 1.

Marketing Authorisation & Yearly Licence of Influenza Vaccines - „Mock-up” & Pre-Pandemic Influenza Vaccines Zsuzsanna Pauliny MD

1 Immune Responses of Healthy Subjects to a Single Dose of Intramuscular Inactivated Influenza A/Vietnam/1203/2004 (H5N1) Vaccine After Priming With an.

Date of download: 7/1/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Immunogenicity of 13-Valent Pneumococcal Conjugate.

Utility of Influenza Vaccination for Oncology Patients Daniel A. Pollyea, Janice M.Y. Brown, and Sandra J. Horning Journal of Clinical Oncolgy; Vol 28.

Effective number of infections

Presenter ITODO EWAOCHE

UN Core Pre-Deployment Training Materials 2017

Copyright © 2014 American Medical Association. All rights reserved.

Copyright © 2007 American Medical Association. All rights reserved.

Volume 135, Issue 3, Pages (September 2008)

Randomized Trial: Immunogenicity and Safety of Coadministered Human Papillomavirus-16/18 AS04-Adjuvanted Vaccine and Combined Hepatitis A and B Vaccine.

U.S. Food and Drug Administration

CD154 Expression Is Associated with Neutralizing Antibody Titer Levels Postinfluenza Vaccination in Stem Cell Transplant Patients and Healthy Adults

A clinical trial of intradermal and intramuscular seasonal influenza vaccination in patients with atopic dermatitis Donald Y.M. Leung, MD, PhD, Brett.

Immunogenicity and Safety of Seasonal Influenza Vaccination in Patients with Classic Kaposi's Sarcoma Monica Cappelletti, Adriano Taddeo, Elena Colombo,

Volume 135, Issue 3, Pages (September 2008)

Tutorial 4 For the Seat Belt Data, the Death Penalty Data, and the University Admission Data, (1). Identify the response variable and the explanatory.

Breadth of binding and HAI activity of serum Ab from i. n. + i. p

Immunization Update 2007 Varicella Vaccine Segment

Antibody Response to Polysaccharide Conjugate Vaccines after Nonmyeloablative Allogeneic Stem Cell Transplantation Aafke Meerveld-Eggink, Ankie M.T.

Protection from influenza virus challenge.

Decreased Antibody Response to Influenza Vaccination in Kidney Transplant Recipients: A Prospective Cohort Study Kelly A. Birdwell, MD, MSCI, Mine R.

Supplemental Figure 1A Pt Pt Pre-treatment

Virus-specific serum antibody response of BALB/c mice to DNA prime followed by VRP boost. Virus-specific serum antibody response of BALB/c mice to DNA.

Immune response to vaccination with AVA in healthy human subjects (human immunogenicity study). Immune response to vaccination with AVA in healthy human.

Serum neutralizing antibody response of BALB/c mice to DNA prime followed by VRP boost. Serum neutralizing antibody response of BALB/c mice to DNA prime.

Refer to word document for this table

Figure 1 Responder rates of patients at 4 weeks compared with prevaccinated levels Responder rates of patients at 4 weeks compared with prevaccinated levels.

Antibody titers against surface antigens of B

RTA-specific serum IgG antibody titers and TNA in mice immunized with RiVax or RVEc. RTA-specific serum IgG titers after the second (A) or third (B) immunizations.

Antibody titers against surface antigens of M

PRAME-specific CD4+ T-cell (TNF-α+/IFN-γ+) immunogenicity scores and cellular response prior to treatment and postdose 4 (ATP cohort for immunogenicity).

Presentation transcript:

Supplemental Digital Content 1 Hemagglutination-inhibition (HI) antibodies against A/New Caledonia/20/99 [H1N1], A/Wisconsin/67/2005 [H3N2] and B/Malaysia/2506/2004 for study vaccine (Fluarix®) and control vaccine (Fluzone®) by age group and previous vaccination history (ATP cohort for immunogenicity) PR1= Previously vaccinated children <3 years PR2 = Previously vaccinated children 3-<5 years UN1 = Children not previously vaccinated <3 years UN2 = Children not previously vaccinated 3-<5 years Fluarix = Fluarix ® 0.25 ml for children <3 years and Fluarix ® 0.5 ml for children 3-<5 years Fluzone = Fluzone ® 0.25 ml for children <3 years and Fluzone ® 0.5 ml for children 3-<5 years PRE = Pre-vaccination dose 1 (Day 0) POST = Post-vaccination timepoint (Day 28 for children previously vaccinated or Day 49 for children not previously vaccinated) GMT = Geometric mean titer (i.e. the anti-log of the mean of the log titer transformations) 95% CI = 95% confidence interval ATP: According-to-protocol; HI: Hemagglutination-inhibition

PR1= Previously vaccinated children <3 years PR2 = Previously vaccinated children 3-<5 years UN1 = Children not previously vaccinated <3 years UN2 = Children not previously vaccinated 3-<5 years Fluarix = Fluarix ® 0.25 ml for children <3 years and Fluarix ® 0.5 ml for children 3-<5 years Fluzone = Fluzone ® 0.25 ml for children <3 years and Fluzone ® 0.5 ml for children 3-<5 years PRE = Pre-vaccination dose 1 (Day 0) POST = Post-vaccination timepoint (Day 28 for children previously vaccinated or Day 49 for children not previously vaccinated) GMT = Geometric mean titer (i.e. the anti-log of the mean of the log titer transformations) 95% CI = 95% confidence interval ATP: According-to-protocol; HI: Hemagglutination-inhibition

PR1= Previously vaccinated children <3 years PR2 = Previously vaccinated children 3-<5 years UN1 = Children not previously vaccinated <3 years UN2 = Children not previously vaccinated 3-<5 years Fluarix = Fluarix ® 0.25 ml for children <3 years and Fluarix ® 0.5 ml for children 3-<5 years Fluzone = Fluzone ® 0.25 ml for children <3 years and Fluzone ® 0.5 ml for children 3-<5 years PRE = Pre-vaccination dose 1 (Day 0) POST = Post-vaccination timepoint (Day 28 for children previously vaccinated or Day 49 for children not previously vaccinated) GMT = Geometric mean titer (i.e. the anti-log of the mean of the log titer transformations) 95% CI = 95% confidence interval ATP: According-to-protocol; HI: Hemagglutination-inhibition